Article Type

Original Study


Objective: To assess circulating lamin B1 (LMNB1) mRNA and glypican-3 cytotoxic T lymphocytes (CTLs) as markers for early detection of hepatocellular carcinoma (HCC). Background: HCC is the fifth most common form of cancer worldwide and the third most common cause of cancer-related deaths. HCC often occurs in the background of a cirrhotic liver. In recent years, surveillance strategies in patients at a higher risk of HCC have led to the diagnosis of the disease at much earlier stages. Patients in early stages have a much higher chance of curative response with different treatment options. Materials and methods: The study included 50 participates, of which 13 were patients with posthepatitis C liver cirrhosis (group I), 13 were patients with early stages of HCC (group IIa), 14 were patients with late stages of HCC (group IIb), and 10 were healthy volunteers with matched age and sex as a control group (group III). The patients were selected from the outpatient clinic and inpatient department of the National Liver Institute, Menoufiya University. LMNB1 mRNA was assessed by reverse transcription-PCR and glypican3 CTLs by flow cytometry and then we compared that with α±-feto protein. Results: Glypican3 CTLs can be used for early detection of HCC patients with 100% specificity and sensitivity. In addition, LMNB1 mRNA can be used in early detection of HCC with specificity and sensitivity 92 and 100%, respectively. Conclusion: Circulating LMNB1 mRNA and glypican3 CTLs can be used as markers for early detection of HCC patients.